Drug Profile
CB AC 02
Alternative Names: Placenta-derived mesenchymal stem cell therapiesLatest Information Update: 25 Oct 2021
Price :
$50
*
At a glance
- Originator CHA Bio & Diostech
- Class Antidementias; Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Alzheimer's disease
Most Recent Events
- 26 Sep 2016 Preclinical trials in Alzheimer's disease in South Korea before September 2016 (IV)
- 26 Sep 2016 CHABiotech plans a phase I/II trial for Alzheimer's disease in South Korea (NCT02899091)